Real-World data to reveal if lung cancer drug combo works equally across ages, races, and sexes

This study will look back at medical records of about 1,000 people in the US with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy as their first treatment. Researchers want to see how well the treatment works and what side effects occur in different groups based on age, sex, race, and ethnicity. The goal is to understand if the treatment is equally effective and safe for everyone in real-world settings.